# Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

> **NCT01508936** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 511 (actual)

## Conditions studied

- Eosinophilic Asthma

## Interventions

- **DRUG:** Reslizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01508936
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2016-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508936, "Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01508936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*